All Oncology News

Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases, were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed. Findings presented at the 19th European Cancer Congress revealed underutilization of a highly effective treatment, due to a lack of referral.

Patients with advanced hepatocellular carcinoma had objective responses and prolonged survival when treated with single-agent nivolumab, data from a dose escalation/expansion trial showed.

The European Commission has expanded the indication for pembrolizumab to include the frontline treatment of patients with metastatic non–small cell lung cancer that expresses PD-L1 on ≥50% of cells and does not harbor an EGFR or ALK mutation.

Pembrolizumab provided durable activity for previously treated patients with mucosal melanoma, according to data coming out of 3 clinical trials.

Patients with lymphoma who are treated with brentuximab vedotin (BV) often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with BV outweigh the risk of neuropathy.

Novel combination approaches are being explored that hope to capitalize on the high rates of complete remissions seen with CAR T-cell therapies for patients with hematologic malignancies.

Jenny C. Chang, MD, discusses the significance of molecular testing in breast cancer and how it will lead to an improvement in treatment approaches in 2017 and beyond.

Peter Martin, MD, discusses the efficacy of a combination regimen of ibrutinib and palbociclib in the treatment of patients with mantle cell lymphoma.

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.

Diagnostic laparoscopy reduced the number of futile laparotomies in patients with suspected advanced-stage ovarian cancer, according to the results of a recent study.

Long or irregular menstrual cycles may be a marker of an increased risk for developing certain subtypes of ovarian cancer, according to the results of a recent study.

Jennifer A. Woyach, MD, discusses the preliminary results of an ongoing phase II trial of MOR208 combination regimens in chronic lymphocytic leukemia.

A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.

Lois Ramondetta, MD, discusses the updated recommendations and the importance of advocating for lesser-known HPV-associated cancers.

Frontline treatment with lenvatinib was shown to be noninferior to standard therapy with sorafenib in patients with unresectable hepatocellular carcinoma.

Saad Z. Usmani, MD, discusses the latest developments with daratumumab in the treatment of patients with multiple myeloma, many of which were presented at the recent 2016 ASH Annual Meeting.

Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.

Neeraj Agarwal, MD, discusses a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors in the treatment of patients with renal cell carcinoma.

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.

Elizabeth Plimack, MD, discusses updated data from the pivotal CheckMate-025 trial, which compared the use of nivolumab with everolimus in the treatment of patients with metastatic renal cell carcinoma.

Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.

Carolyn E. Banister, MD, discusses the results of a study that uncovered a new subtype of cervical cancer, as well as some of the remaining challenges in the overall treatment landscape.

Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.

David Albala, MD, discusses the uses and benefits of robotic urological surgery in prostate cancer, as well as methods to achieve better physician compliance.

Franco M. Muggia, MD, discusses the results of the Gynecologic Oncology Group (GOG) 252 trial and what the findings mean regarding intraperitoneal therapy for patients with ovarian cancer.

Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

David F. McDermott, MD, discusses ongoing efforts to improve outcomes in advanced renal cell carcinoma through combination anti–VEGF/PD-1 regimens.

The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.

Scientists from the Sidney Kimmel Cancer Center at Thomas Jefferson University have pinpointed a survival protein for patients suffering from non-Hodgkin's lymphoma.

Researchers at Yale Cancer Center and Yale Medicine have identified the critical target of new immune-checkpoint therapies: subsets of immune cells called tissue resident memory (TRM) T cells. In the same research, scientists also found that individual metastatic cancer lesions contain unique sets of TRM cells.